These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 15367588)

  • 41. Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate.
    Kantor J; Irvine K; Abrams S; Snoy P; Olsen R; Greiner J; Kaufman H; Eggensperger D; Schlom J
    Cancer Res; 1992 Dec; 52(24):6917-25. PubMed ID: 1458480
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antibody against extracellular vaccinia virus (EV) protects mice through complement and Fc receptors.
    Cohen ME; Xiao Y; Eisenberg RJ; Cohen GH; Isaacs SN
    PLoS One; 2011; 6(6):e20597. PubMed ID: 21687676
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Modified vaccinia virus Ankara immunization protects against lethal challenge with recombinant vaccinia virus expressing murine interleukin-4.
    McCurdy LH; Rutigliano JA; Johnson TR; Chen M; Graham BS
    J Virol; 2004 Nov; 78(22):12471-9. PubMed ID: 15507634
    [TBL] [Abstract][Full Text] [Related]  

  • 44. L1R, A27L, A33R and B5R vaccinia virus genes expressed by fowlpox recombinants as putative novel orthopoxvirus vaccines.
    Pacchioni SM; Bissa M; Zanotto C; Morghen Cde G; Illiano E; Radaelli A
    J Transl Med; 2013 Apr; 11():95. PubMed ID: 23578094
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Major neutralizing sites on vaccinia virus glycoprotein B5 are exposed differently on variola virus ortholog B6.
    Aldaz-Carroll L; Xiao Y; Whitbeck JC; de Leon MP; Lou H; Kim M; Yu J; Reinherz EL; Isaacs SN; Eisenberg RJ; Cohen GH
    J Virol; 2007 Aug; 81(15):8131-9. PubMed ID: 17522205
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antibody responses to vaccinia membrane proteins after smallpox vaccination.
    Lawrence SJ; Lottenbach KR; Newman FK; Buller RM; Bellone CJ; Chen JJ; Cohen GH; Eisenberg RJ; Belshe RB; Stanley SL; Frey SE
    J Infect Dis; 2007 Jul; 196(2):220-9. PubMed ID: 17570109
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Engineering the vaccinia virus L1 protein for increased neutralizing antibody response after DNA immunization.
    Shinoda K; Wyatt LS; Irvine KR; Moss B
    Virol J; 2009 Mar; 6():28. PubMed ID: 19257896
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Adsorption of recombinant poxvirus L1-protein to aluminum hydroxide/CpG vaccine adjuvants enhances immune responses and protection of mice from vaccinia virus challenge.
    Xiao Y; Zeng Y; Alexander E; Mehta S; Joshi SB; Buchman GW; Volkin DB; Middaugh CR; Isaacs SN
    Vaccine; 2013 Jan; 31(2):319-26. PubMed ID: 23153450
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunogenicity of Nef protein of SIVSMM-PBj14 expressed in a live vaccine strain of Salmonella species.
    Cattozzo EM; Stocker BA
    AIDS Res Hum Retroviruses; 1994 Aug; 10(8):1011-9. PubMed ID: 7811532
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vaccination with Venezuelan equine encephalitis replicons encoding cowpox virus structural proteins protects mice from intranasal cowpox virus challenge.
    Thornburg NJ; Ray CA; Collier ML; Liao HX; Pickup DJ; Johnston RE
    Virology; 2007 Jun; 362(2):441-52. PubMed ID: 17292434
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Protection of guinea pigs from Lassa fever by vaccinia virus recombinants expressing the nucleoprotein or the envelope glycoproteins of Lassa virus.
    Morrison HG; Bauer SP; Lange JV; Esposito JJ; McCormick JB; Auperin DD
    Virology; 1989 Jul; 171(1):179-88. PubMed ID: 2741340
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Protection against EHV-1 challenge infection in the murine model after vaccination with various formulations of recombinant glycoprotein gp14 (gB).
    Osterrieder N; Wagner R; Brandmüller C; Schmidt P; Wolf H; Kaaden OR
    Virology; 1995 Apr; 208(2):500-10. PubMed ID: 7747423
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Recombinant A27 protein synergizes with modified vaccinia Ankara in conferring protection against a lethal vaccinia virus challenge.
    He Y; Meseda CA; Vassell RA; Merchlinsky M; Weir JP; Weiss CD
    Vaccine; 2010 Jan; 28(3):699-706. PubMed ID: 19887133
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge.
    Wyatt LS; Earl PL; Eller LA; Moss B
    Proc Natl Acad Sci U S A; 2004 Mar; 101(13):4590-5. PubMed ID: 15070762
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunogenicity of baculovirus expressed recombinant proteins of Japanese encephalitis virus in mice.
    Yang DK; Kweon CH; Kim BH; Lim SI; Kwon JH; Kim SH; Song JY; Han HR
    J Vet Sci; 2005 Jun; 6(2):125-33. PubMed ID: 15933432
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.
    Meseda CA; Garcia AD; Kumar A; Mayer AE; Manischewitz J; King LR; Golding H; Merchlinsky M; Weir JP
    Virology; 2005 Sep; 339(2):164-75. PubMed ID: 15993917
    [TBL] [Abstract][Full Text] [Related]  

  • 57. DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge.
    Hooper JW; Custer DM; Schmaljohn CS; Schmaljohn AL
    Virology; 2000 Jan; 266(2):329-39. PubMed ID: 10639319
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anti-viral protection and prevention of lymphocytic choriomeningitis or of the local footpad swelling reaction in mice by immunization with vaccinia-recombinant virus expressing LCMV-WE nucleoprotein or glycoprotein.
    Hany M; Oehen S; Schulz M; Hengartner H; Mackett M; Bishop DH; Overton H; Zinkernagel RM
    Eur J Immunol; 1989 Mar; 19(3):417-24. PubMed ID: 2468501
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin.
    Bell E; Shamim M; Whitbeck JC; Sfyroera G; Lambris JD; Isaacs SN
    Virology; 2004 Aug; 325(2):425-31. PubMed ID: 15246280
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Recombinant Semliki Forest virus particles encoding the prME or NS1 proteins of louping ill virus protect mice from lethal challenge.
    Fleeton MN; Sheahan BJ; Gould EA; Atkins GJ; Liljestr M P
    J Gen Virol; 1999 May; 80 ( Pt 5)():1189-1198. PubMed ID: 10355766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.